[The cardiovascular outcome is critical].
.
Peter
P
Stiefelhagen
D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D048909:Diabetes Complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000009:adverse effects / Q000627:therapeutic use*
D001559:Benzhydryl Compounds; D059451:Biosimilar Pharmaceuticals; D005960:Glucosides; D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; C570240:empagliflozin